Madison, Wis.-based Exact Sciences Corp. is a molecular diagnostics company dedicated to eradicating colon cancer.
Here are six things to know.
1. Exact Sciences' flagship product Cologuard is the first noninvasive screening test for colorectal cancer that assesses both stool DNA and blood biomarkers.
2. In a 2014 clinical study in NEJM, Cologuard found 92 percent of colon cancers and 69 percent of the most advanced pre-cancerous polyps in average risk patients.
3. Cologuard is intended for use by people aged 50 and older at average risk for colorectal cancer. The screening test can be performed at home.
4. AbbVie's former Vice President of U.S. Immunology Mark Stenhouse recently joined Exact Sciences as president of the Cologuard product.
5. Exact Sciences' The New 50 campaign aims to encourage people aged 50 years or older to talk with their healthcare provider about getting screened for colon cancer.
6. The company partnered with award-winning singer and actor Harry Connick, Jr., and former model and cancer survivor Jill Connick to support The New 50.
More articles on gastroenterology:
70% of minimally invasive esophagectomy patients back to work 1 year postoperatively: 6 insights
Sen. John McCain in stable condition after intestinal surgery — 4 insights